Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase 1 3Phase 3 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Hodgkin Disease 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Rituximab 16Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 11fludarabine phosphate 10Cytarabine 9Methotrexate 8Vincristine 7blinatumomab 6Filgrastim 6Etoposide 6fludarabine 5Prednisone 5Mycophenolic Acid 5Lenalidomide 5Dexamethasone 5Cyclosporine 5merphos 4Whole-Body Irradiation 4Radiotherapy 4Ifosfamide 4Carboplatin 4venetoclax 3romidepsin 3prednylidene 3deltacortene 3Spinal Puncture 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Inotuzumab Ozogamicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Burkitt Lymphoma × Spinal Puncture × Clear all
NCT03504644 2026-05-29

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Eastern Cooperative Oncology Group

Phase 1/2 Active not recruiting
40 enrolled 18 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07069699 2026-05-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

National Cancer Institute (NCI)

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Burkitt Lymphoma

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡